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Objective. Neutrophils are the most abundant innate immune cells in the blood, but little is known about their role in (acquired) chronic autoinflammatory diseases. This study was undertaken to investigate the role of neutrophils in systemic-onset juvenile idiopathic arthritis (JIA), a prototypical multifactorial autoinflammatory disease that is characterized by arthritis and severe systemic inflammation.
Methods. Fifty patients with systemic-onset JIA who were receiving treatment with recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) were analyzed at disease onset and during remission. RNA sequencing was performed on fluorescence-activated cell-sorted neutrophils from 3 patients with active systemic-onset JIA and 3 healthy controls. Expression of activation markers, apoptosis, production of reactive oxygen species (ROS), and degranulation of secretory vesicles from neutrophils were assessed by flow cytometry in serum samples from 17 patients with systemic-onset JIA and 15 healthy controls.
Results. Neutrophil counts were markedly increased at disease onset, and this correlated with the levels of inflammatory mediators. The neutrophil counts normalized within days after the initiation of rIL-1Ra therapy. RNA-sequencing analysis revealed a substantial up-regulation of inflammatory processes in neutrophils from patients with active systemic-onset JIA, significantly overlapping with the transcriptome of sepsis. Correspondingly, neutrophils from patients with active systemic-onset JIA displayed a primed phenotype that was characterized by increased ROS production, CD62L shedding, and secretory vesicle degranulation, which was reversed by rIL-1Ra treatment in patients who had achieved clinical remission. Patients with a short disease duration had high neutrophil counts, more immature neutrophils, and a complete response to rIL-1Ra, whereas patients with symptoms for >1 month had normal neutrophil counts and an unsatisfactory response to rIL-1Ra. In vitro, rIL-1Ra antagonized the priming effect of IL-1b on neutrophils from healthy subjects.
Conclusion. These results strongly support the notion that neutrophils play an important role in systemic-onset JIA, especially in the early inflammatory phase of the disease. The findings also demonstrate that neutrophil numbers and the inflammatory activity of systemic-onset JIA are both susceptible to IL-1 blockade.
hepatosplenomegaly, and/or serositis (1) . The systemic inflammation is reflected by elevations in the parameters of inflammation, including an increased erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and ferritin level. Moreover, patients with systemic-onset JIA have shown a good response to therapeutic blockade of either interleukin-1 (IL-1) or IL-6 (2). However, some patients fail to respond to IL-1 or IL-6 blocking therapy.
It is hypothesized that autoinflammatory features, including an IL-1 signature, are most prominent in the early phase of the disease, while later in the disease course, more adaptive immune mechanisms come into play, which might explain why higher response rates have been observed in studies using IL-1 blockade as first-line therapy as compared to studies in which IL-1 blockade was initiated later in the disease course (1) (2) (3) (4) . However, this is still under debate, as the pathogenesis of systemic-onset JIA remains largely unresolved.
A prominent feature of systemic-onset JIA is the marked neutrophilia that develops during active disease (5) . Besides phagocytosis, neutrophils can perform a variety of functions, including release of (bactericidal) granular proteins and reactive oxygen species (ROS) (6) . Furthermore, neutrophils are a major source of S100A8/ A9 and S100A12 proteins, which are found at extremely high levels in patients with active systemic-onset JIA (7) (8) (9) . Because of their increased numbers and their release of inflammatory mediators, neutrophils could be a major contributor to the inflammatory cascade of systemic-onset JIA. However, studies on the role of neutrophils in the pathogenesis of systemic-onset JIA are lacking. We therefore investigated the phenotype and function of neutrophils from patients with systemic-onset JIA, using a combination of clinical data and primary patient material from a prospective systemic-onset JIA cohort (4) .
PATIENTS AND METHODS
Patients. All patients with systemic-onset JIA were treated at the University Medical Center Utrecht (UMCU) in The Netherlands as part of a prospective cohort study on the efficacy of recombinant IL-1 receptor antagonist (rIL-1Ra; anakinra) as first-line treatment (4) . In short, patients with systemic-onset JIA were started on rIL-1Ra treatment at a dosage of 2 mg/kg per day subcutaneously after prior treatment with nonsteroidal antiinflammatory drugs had been unsuccessful. When the disease became clinically inactive, the dosage of rIL-1Ra was tapered off over a period of 3 months. In patients with persistent symptoms, corticosteroids were added to the rIL-1Ra treatment regimen; if that failed, patient treatments were switched to an alternative biologic agent.
Clinical and laboratory data were obtained from all patients (results shown in Figures 1A-D) . Protein concentrations were measured in patients for whom serum samples were available at the time of disease onset or during remission (results shown in Figures 1E and F Figures 2-6 ) were performed in a subset of 9 patients with active systemic-onset JIA and 8 patients who were in remission. Supplementary Table 2 (available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40442/abstract) shows detailed information on the baseline characteristics of these 17 patients. As a control, blood was obtained from adult volunteers who were participating in the local donor service of UMCU; the median age of the healthy control subjects was 39 years (interquartile range 29-50 years).
The study was approved by the institutional ethics review board of UMCU. All patients and volunteers provided written informed consent.
Determination of serum compounds. Serum samples from patients with systemic-onset JIA were assessed for circulating levels of neutrophil-related proteins using a multiplex immunoassay, as described previously (10) . Levels of S100A12 and S100A8/A9 in the serum and supernatant of stimulated neutrophils were measured by sandwich enzyme-linked immunosorbent assay.
Cell isolation and neutrophil selection. Blood was collected in sodium heparin tubes and processed <1 hour after withdrawal. Erythrocytes were lysed in a solution of cold isotonic ammonium chloride (155 mM)-potassium carbonate (10 mM)-EDTA (0.1 mM) for 15 minutes, followed by centrifugation at 4°C and washing steps with isolation buffer (phosphate buffered saline supplemented with 10% pasteurized plasma solution and 0.4% trisodium citrate).
For RNA-sequencing analyses and reverse transcriptionquantitative polymerase chain reaction (RT-qPCR), neutrophils were sorted using a FACSAria III fluorescence-activated cell sorter (FACS) (BD Biosciences) based on their forward/ side light-scatter patterns, positive expression of CD16, and negative expression of CD14 and CD41 (see Supplementary Figure 1A for a depiction of the gating strategy, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40442/abstract). For all other experiments, whole blood leukocytes were used; gating of neutrophils was performed during flow cytometry analysis (see Supplementary Figure 2A , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40442/abstract).
Analysis of ROS production and degranulation. Cells (10 6 /ml) were distributed in U-shaped 96-well plates in neutrophil culture medium (20 mM HEPES, 132 mM NaCl, 6 mM KCl, 1 mM MgSO 4 , and 1.2 mM KH 2 PO 4 , supplemented with 5 mM glucose, 1 mM CaCl 2 , and 0.5% human albumin). The plates were placed in an incubator with an atmosphere of 5% CO 2 at 37°C, unless otherwise specified.
For ROS assays, whole blood leukocytes were incubated with 0.1 lM of the ROS-responsive dye dihydrorhodamine (DHR) (Sigma-Aldrich) for 5 minutes, and subsequently stimulated with 10 lM fMLP (Sigma-Aldrich) for 15 minutes. For CD62L and degranulation assays, 100 ll whole blood was stimulated with 10 lM fMLP for 15 minutes, and subsequently, lysing A, Neutrophil, monocyte, and lymphocyte counts obtained by routine clinical laboratory measurements in the serum of patients at disease onset (n = 50) and during clinical remission after 3 months of receiving recombinant interleukin-1 receptor antagonist (rIL-1Ra) (n = 31). Shaded areas indicate the boundaries of a normal cell count for healthy children (pediatric reference values). B, Neutrophil counts before and during the first week of rIL-1Ra therapy. C, Correlation between the number of days since the first disease manifestation and neutrophil counts at disease onset (n = 48). D, Correlation between the levels of the acute-phase proteins C-reactive protein (CRP) (n = 47) and ferritin (n = 44) and neutrophil counts at disease onset. E, Serum levels of the neutrophil-related proteins S100A8/A9, S100A12, matrix metalloproteinase 8 (MMP-8), MMP-9, elastase, soluble E-selectin (sE-selectin), and soluble intercellular adhesion molecule 1 (sICAM-1) at disease onset (n = 17-18) and during clinical remission after 3 months of receiving rIL-1Ra (n = 21). F, Correlation between neutrophil counts and serum levels of S100A8/A9, S100A12, MMP-8, and soluble E-selectin at disease onset (n = 16-17 For assays of cell apoptosis, neutrophils were stained with annexin V-APC (550474, concentration 1/100) and 7-aminoactinomycin D (7-AAD) (559925, concentration 1/100) in annexin binding buffer for 15 minutes at room temperature, as indicated by the manufacturer (BD Biosciences). Live cells were defined as those that stained negative for annexin V and 7-AAD.
RNA sequencing and RT-qPCR. Neutrophils were lysed in TRIzol LS reagent (Thermo Fisher) directly after sorting. RNA was isolated according to the manufacturer's protocol. The concentration of RNA was quantified using a Qubit RNA HS assay and Qubit fluorometer (Thermo Fisher). Polyadenylated messenger RNA was isolated using Poly(A) beads (NEXTflex), and sequencing libraries were made using the Rapid Directional RNA-seq kit (NEXTflex). Libraries were sequenced at the Utrecht Sequencing Facility using the Nextseq500 platform (Illumina), which produced single end reads of 75 bp. Reads were aligned to the human reference genome GRCh37 using STAR version 2.4.2a. Picard's AddOrReplaceReadGroups (version 1.98) was used to add read groups to the binary sequence alignment files, which were sorted using Sambamba (version 0.4.5), and transcript abundances were quantified with HTSeq-count (version 0.6.1p1) using the union mode. Subsequently, reads per kilobase per million reads sequenced (RPKMs) were calculated with the edgeR RPKM function.
Differentially expressed genes were identified using the DESeq2 package with standard settings. Genes with an absolute log 2 fold change larger than 0.6 and adjusted P values of less than 0.1 were considered to be differentially expressed genes. RNA-sequencing data have been deposited in the NCBI GEO data repository (11) (accessible through GEO Series accession no. GSE103170) (12). Differentially expressed genes were entered in ToppGene (13). Differentially expressed genes from publicly available microarray data sets were derived using GEO2R with default settings (11, 14) , and these gene sets were entered in the gene set enrichment analysis (15) .
For RT-qPCR, isolated RNA was processed using a Script complementary DNA synthesis kit (Bio-Rad) and SYBR Select Master Mix (Applied Biosystems). RT-qPCR was performed on a QuantStudio 12K (Thermo Fisher) using the following primers: for B2M, forward TGCTGTCTCCATGTTTGATGTATCT and reverse TCTCTGCTCCCCACCTCTAAGT; for NFKB1, forward CAGATGGCCCATACCTTCAAAT and reverse CGGAAAC GAAATCCTCTCTGTT; and for IL1B, forward GCTGAGGAA GATGCTGGTTC and reverse TCCATATCCTGTCCCTGGAG.
Statistical analysis. Statistical analyses were performed using the IBM SPSS Statistics program (version 21). Comparisons of distributions between 2 groups or between 3 groups were made by Mann-Whitney U test or Kruskal-Wallis test (including Dunn-Bonferroni post hoc correction [16] ), respectively, and pairwise comparisons were performed using Wilcoxon's signed rank test. Correlations between 2 variables were tested with Spearman's rho correlation coefficients. Graphs were prepared in Graphpad Prism (version 7.02).
RESULTS
Rapid normalization of neutrophil counts following IL-1 blockade in patients with systemic-onset JIA, and correlation of neutrophil counts with parameters of inflammation. Using data from routine clinical laboratory measurements, we confirmed earlier findings of neutrophilia (5) in our cohort of 50 patients with systemic-onset JIA at the time of disease onset. Neutrophil counts were markedly elevated in 40 of 50 patients (median 11.9 9 10 9 / liter, interquartile range 8.4-16.5 9 10 9 /liter) ( Figure 1A ). In contrast, monocyte counts were elevated in only 14 of 50 patients, and no patient had increased lymphocyte counts when compared to pediatric reference values ( Figure 1A ). During inactive disease, at 3 months after the start of therapy with human rIL-1Ra (anakinra), all patients had normal neutrophil counts ( Figure 1A ). Strikingly, consistent with the rapid clinical improvement observed, neutrophil counts normalized in all patients within 1 day after initiation of rIL-1Ra therapy ( Figure 1B ).
Since we observed a substantial variability in the neutrophil counts in patients at the time of disease onset, we assessed correlations of the neutrophil counts with the available clinical information from each patient at the first visit. Disease duration correlated significantly with neutrophil counts, e.g., patients with a short interval between the onset of symptoms and first visit to the hospital had higher neutrophil counts than did patients who had symptoms for more than 1 month ( Figure 1C ). Furthermore, levels of acute-phase proteins (CRP and ferritin) correlated significantly with the neutrophil counts ( Figure 1D ). Monocyte and lymphocyte counts did not correlate with these variables (see Supplementary Figures 3A TER HAAR ET AL counts and the age of the patients, other leukocyte counts, or ESR was found (data not shown). Collectively, these data confirm that there was an abundance of neutrophils in patients with systemic-onset JIA, especially in the early inflammatory phase of the disease, with a rapid normalization of neutrophil counts following therapy with rIL-1Ra.
Increased levels of neutrophil-related proteins at disease onset in patients with systemic-onset JIA. To further address the role of neutrophils in systemic-onset JIA, we analyzed the serum levels of several neutrophilrelated proteins. As previously reported (7-9), we confirmed that the levels of S100A8/A9 and S100A12 were significantly elevated in patients with systemic-onset JIA at the time of disease onset as compared to the time of remission at 3 months after the initiation of rIL-1Ra therapy ( Figure 1E) .
Moreover, other components of neutrophil granules (17, 18) UPP1  ZDHHC19  LAIR1  NOV  ANGPT1  ADM  TBC1D8  SPATC1  P2RY10  CACNB4  MCEMP1  ADGRE1  CTD-3065J16.6  KIFC3  PLAC8  HP  ITGA7  CDK5RAP2  SLC1A3  CST7  TPST1  FCGR1A  LILRA5  FLVCR2  GYG1  CCDC71L  BATF  HK3  PPM1N  SLC51A  ANXA3  CD48  RP11-473M20.9  MPEG1  CNIH4  ADAM28  NKX3-1  IRAK3  CPNE5  TLR5  PLSCR1  LMNB1  MLLT4  RABGAP1L  DDIAS  SLC26A8  AC091878.1  SLC2A14  TSPEAR  CD44  TRPM2  IL4R  AIM2  SLAMF7  CD274  NECAB1  SCN1B  S100A8  CASP5  ABCA2  RELL1  TIFA  GRINA  C1orf132  FCGR1B  DMPK  CLEC4D  FSTL4  SAMSN1  GCH1  ARID5B  VWF  ATP9A  GABBR1  RHOU  MPZL1  S100A12  MSL3  GPR162  PNKD  HRH4  CLEC9A  GPX3  MTURN  MTRR  CCDC101  E2F2  RP11-531H8.2  INSL3  HSD3B7  FFAR3  RHOC  LINC01093  RP11-701P16.5  TOMM40L  MAPK14  ARRB1  TP53INP2 Figure 3 . Up-regulation of inflammatory genes in neutrophils from patients with systemic-onset juvenile idiopathic arthritis (sJIA). RNA-sequencing analysis was performed following fluorescence-activated cell sorting of CD16+CD14ÀCD41À neutrophils from 3 patients with active systemic-onset JIA and 3 adult healthy controls (HCs) (further details on the gating strategy are given in Supplementary Figure 1A , http://onlinelibrary.wiley.com/ doi/10.1002/art.40442/abstract). A, Principal components (PC) analysis of neutrophil gene expression using the top 1,000 most variable genes. B, Vulcano plot of neutrophil gene expression. Differentially expressed genes (adjusted P < 0.1 and log 2 fold change <0.6) are depicted in red. C, Top 10 most significant biologic processes derived from the differentially expressed genes, as identified by gene ontology (GO) analysis. Values in parentheses are the number of differentially expressed genes/total number of genes in the annotated process. D, Heatmap of the differentially expressed genes associated with the GO biologic process "immune response," with key genes highlighted. Colors indicate normalized gene expression (yellow = high expression, blue = low expression). E, Expression levels of selected differentially expressed genes in the peripheral blood of 3 patients with active systemic-onset JIA and 3 healthy controls. Adjusted P values were derived from RNA-sequencing analysis. Bars show the median with interquartile range. F, Gene set enrichment analysis of gene sets from patients with experimental endotoxemia (LPS iv) (GEO accession no. GSE35590) and patients with sepsis (GEO accession no. GSE64456), analyzing up-regulated (UP) or down-regulated (DN) genes in comparison to time 0 (left) or to healthy controls (right). G, Heatmap of log 2 fold changes in gene expression relative to healthy controls, in neutrophils from patients with active systemic-onset JIA, patients with endotoxemia, and patients with sepsis. Red indicates up-regulation versus controls, while blue indicates down-regulation; missing data are depicted in gray. The selection of genes was based on the top 100 most differentially expressed genes in patients with systemic-onset JIA, according to adjusted P values. ES = enrichment score; NES = normalized enrichment score; q = false discovery rate-corrected P value. significantly increased levels at disease onset compared to their levels at the time of remission with rIL-1Ra treatment ( Figure 1E ). Notably, neutrophil counts significantly correlated with the levels of S100A8/A9, S100A12, MMP-8, and soluble E-selectin ( Figure 1F ), whereas monocyte counts were not correlated with the levels of MMP-8 and soluble E-selectin. Monocyte counts were even negatively correlated with the levels of S100A8/A9 and S100A12 (see Supplementary Figure 3C , http://onlinelibrary.wiley.com/doi/10.1002/art. 40442/abstract). The increased levels of neutrophilrelated proteins and the correlation with neutrophil counts may serve to support the notion that neutrophils play an important role in the inflammatory response of systemic-onset JIA. More immature and primed neutrophils in the peripheral blood of patients with systemic-onset JIA. As we observed a marked neutrophilia at disease onset in patients with systemic-onset JIA, we aimed to characterize the neutrophils in these patients. In the peripheral blood of patients with other causes of systemic inflammation, namely sepsis and experimental endotoxemia, a profound shift in neutrophil subsets has been described (19, 20) . In noninflammatory conditions, nearly all circulating neutrophils express high levels of CD16 (Fcc receptor type III) and CD62L (Lselectin) and have a normal segmented nucleus (so-called "mature neutrophils"). In contrast, in systemic inflammation, 20-25% of the neutrophils are CD16 dim with a banded nucleus (i.e., "immature neutrophils"), and 10-15% are CD62L dim with an increased number of nuclear lobes. These subsets were found to be present in patients with systemic-onset JIA during the time of active disease. The total neutrophil population in these patients comprised 10-15% immature, CD16 dim neutrophils (Figures 2A and B) . The finding of significantly increased percentages of immature neutrophils (banded neutrophils and granulocyte precursors) was confirmed by cell morphology ( Figures 2C and D) . There was a tendency toward increased percentages of CD62L dim neutrophils in patients with active systemic-onset JIA ( Figure 2B ), but these neutrophils did not have an increased number of nuclear lobes ( Figure 2D ).
TER HAAR ET AL
Since CD62L can be shed upon stimulation, the decreased production of CD62L in neutrophils could be a reflection of the "primed" state of the neutrophils (21) (22) (23) . Neutrophil priming is defined as the transition toward enhanced responsiveness, and the primed phenotype includes altered receptor expression, enhanced respiratory burst, and increased degranulation, especially after a second stimulus (23) . These phenotypic changes occur after in vitro stimulation (e.g., by cytokines or microbial products) or in vivo in inflammatory conditions, such as infections and rheumatic diseases, and generally result in an amplification of the inflammatory response (23) . Next to increased CD62L shedding, other signs of neutrophil priming, such as toxic granules and vacuoles (24) , were identified in the majority of patients with active systemic-onset JIA (Figure 2D) . Neutrophils of patients in disease remission had a normal mature phenotype, similar to that in healthy controls (Figures 2A-D) . Taken together, these findings indicate that more immature neutrophils and neutrophils with a primed phenotype are characteristics detected in patients with active systemic-onset JIA.
Up-regulation of inflammatory genes with a sepsis-like signature by neutrophils from patients with systemic-onset JIA. To investigate the transcriptome of neutrophils, we performed RNA-sequencing analysis of 
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Complete response to rIL-1RA Insufficient response to rIL-1RA Figure 5 . Better response to treatment with recombinant interleukin-1 receptor antagonist (rIL-1Ra) in patients with systemic-onset juvenile idiopathic arthritis (sJIA) who had a short interval between the onset of symptoms and first visit to the hospital and who displayed high neutrophil counts. The relationship between disease duration at first presentation and the neutrophil counts from routine clinical laboratory measurements at disease onset (A) or between disease duration at first presentation and the percentage of immature, CD16 dim neutrophils among the total neutrophil population at disease onset (B) was determined in a subset of 7 patients with systemic-onset JIA. Due to the limited number of patients, statistical tests were not performed. Gene ontology (GO) analysis of the biologic processes associated with the differentially expressed genes observed in patients with systemic-onset JIA indicated a very strong enrichment of immune responses in their neutrophils ( Figure 3C ). The majority of these immunerelated genes were expressed at higher levels in patients with systemic-onset JIA compared to healthy controls ( Figure 3D ). Separate GO analyses revealed that only the up-regulated genes in patients with systemic-onset JIA contributed to the enrichment of immune-related processes (see Supplementary Figures 1E and F , http:// onlinelibrary.wiley.com/doi/10.1002/art.40442/abstract). Up-regulated genes in systemic-onset JIA included S100 proteins, IL-1 family members, components of inflammasomes, and genes belonging to the NF-jB pathway ( Figure 3E ).
To identify potential factors that could activate the transcription of immune-related genes, we performed an analysis of upstream regulators. This analysis revealed lipopolysaccharide (LPS) to be the most significant regulator of the gene changes observed in the neutrophils from patients with systemic-onset JIA (see Supplementary Figure 1G , http://onlinelibrary.wiley. com/doi/10.1002/art.40442/abstract). LPS is a component of the outer membrane of gram-negative bacteria and elicits strong immune responses via Toll-like receptor 4 (TLR-4), as is commonly seen in patients with sepsis. Because systemic-onset JIA is characterized by high levels of circulating TLR-4-binding S100A8/A9 and S100A12 proteins, we hypothesized that the immune activation of neutrophils observed in systemic-onset JIA might be similar to the neutrophil response seen in (LPS-mediated) sepsis. Indeed, in our study we found a significant enrichment of differentially expressed genes in neutrophils during bacterial sepsis (GEO accession no. GSE64457 [22] ) and in neutrophils from patients with experimental endotoxemia (GEO accession no. GSE35590 [25] ) ( Figure 3F) . Correspondingly, the majority of the top 100 differentially expressed genes identified in patients with systemic-onset JIA were also differentially expressed in patients with sepsis or experimental endotoxemia ( Figure 3G ). Thus, our data indicate a strong similarity of neutrophil phenotype and activation during systemic inflammation between systemic-onset JIA and sepsis.
Evidence of a primed phenotype in neutrophils from patients with systemic-onset JIA. Since we observed signs of neutrophil priming based on the morphologic features of the cells and on gene expression data, we explored the phenotype of neutrophils in patients with systemic-onset JIA in more detail. Data from ex vivo flow cytometry analysis confirmed a decreased surface expression of CD16 and CD62L and showed an increased expression of CD64 (Fcc receptor type I) and CD35 (a marker of secretory vesicle degranulation [26] ) in neutrophils from patients with systemic-onset JIA whose disease was active as compared to healthy controls, whereas patients in remission had expression levels similar to those in healthy controls ( Figure 4A We further investigated the degranulation of secretory vesicles after in vitro stimulation with fMLP, a chemotactic peptide that induces a rapid and almost complete degranulation of secretory vesicles (26) . Compared to neutrophils in a steady state, primed neutrophils show an enhanced degranulation and increased ROS production upon activation with fMLP (23) . Consistent with the ex vivo data, higher surface expression of CD35 was also observed in vitro in patients with active systemic-onset JIA compared to healthy controls. Stimulation with fMLP led to even higher expression of CD35 ( Figure 4B ). Degranulation of gelatinase granules (as judged by surface expression of CD11b) and specific granules (CD66b) was not significantly increased in patients with systemic-onset JIA (see Supplementary Figures 2D and E, http://onlinelibrary.wiley. com/doi/10.1002/art.40442/abstract).
Secretory vesicles are known to contain high levels of S100 proteins (17) , suggesting that an increased degranulation of these vesicles could contribute to the 952 TER HAAR ET AL high serum levels of S100 proteins found in these patients. However, when the S100A8/A9 protein concentrations were analyzed in the supernatant of stimulated neutrophils, no differences were found between patients with systemic-onset JIA and healthy controls, nor were there any differences in the protein concentrations between supernatants with fMLP stimulation and supernatants with medium control ( Figure 4C ). Thus, we found no evidence to indicate that the secretion of S100 proteins per neutrophil was increased. However, as the neutrophil counts were highly elevated in patients with systemic-onset JIA and correlated with the levels of S100A8/A9 and S100A12 ( Figure 1F ), neutrophils may still be the major source of the observed high serum levels of S100A8/A9 and S100A12 in these patients. Consistent with the primed phenotype of neutrophils observed ex vivo, the expression of CD62L on neutrophils after a short in vitro culture was significantly lower in patients with active systemic-onset JIA compared to healthy controls ( Figure 4D ). Furthermore, ROS production after fMLP stimulation was increased in patients with active systemic-onset JIA compared to patients in remission or compared to healthy controls ( Figure 4E ). Therefore, these results indicate that neutrophils from patients with active systemic-onset JIA are primed by inflammatory mediators in vivo.
More immature neutrophils and better response to rIL-1Ra treatment in patients with a short disease duration. For the characterization of neutrophils in active systemic-onset JIA, we studied blood from 7 patients with systemic-onset JIA at the time of disease onset. Three of these patients had already been experiencing symptoms for more than 1 month when they first visited our hospital (1 patient [patient sJIA1 in Figure 5 ] had skin rash for 9 months, and fever and arthritis for 1-2 weeks; 1 patient [patient sJIA6 in Figure 5 ] had skin rash for 3 months, arthritis for 2 months, and fever for 2 weeks; 1 patient [patient sJIA8 in Figure 5 ] had skin rash and fever for 2 months, and arthritis for 6 weeks). In the other 4 patients (patients sJIA2, sJIA4, sJIA5, and sJIA9 in Figure 5 ), symptoms (including fever) started <1 month before the first visit to our clinic (see Supplementary Table 2 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40442/abstract). Consistent with the findings shown in Figure 1C , patients with a short disease duration had high neutrophil counts, whereas patients with a disease duration of >1 month had normal or only minimally elevated neutrophil counts ( Figure 5A) . Moreover, the percentage of immature neutrophils within the total neutrophil population was substantially higher in patients with a short disease duration ( Figure 5B ). Strikingly, the 4 patients with a disease duration of <1 month and high neutrophil counts had a complete response to first-line therapy with rIL-1Ra and were able to achieve clinical remission while off medication, within 1 year after the initiation of therapy. In contrast, the 3 patients with a disease duration of >1 month and normal neutrophil counts did not achieve inactive disease following rIL-1Ra monotherapy (Figures 5A and B; see also Supplementary Table 2) , and ultimately these patients were switched to an alternative biologic agent. Albeit in a small number of patients, these observations support the hypothesis that neutrophils play a role in the early acute phase of the disease and are susceptible to IL-1 blockade.
Priming of neutrophils by IL-1b, and reversion of the primed phenotype by rIL-1Ra. To further investigate the effects of IL-1b and rIL-1Ra on neutrophils, we cultured healthy control neutrophils in the presence of IL-1b, with or without preincubation with rIL-1Ra. Consistent with previous findings (27) , IL-1b increased the percentage of live cells after 20 hours in culture, which was abrogated by preincubation with rIL-1Ra ( Figure 6A ).
Delayed apoptosis of neutrophils is also described in patients with systemic inflammation (28, 29) . However, we found no significant difference in the number of apoptotic cells between patients with active systemic-onset JIA and patients in remission or healthy controls ( Figure 6B ).
After in vitro incubation with IL-1b, neutrophils showed enhanced shedding of CD62L following stimulation with fMLP, which was reversed by preincubation with rIL-1Ra ( Figure 6C ). Interestingly, stimulation of neutrophils with IL-1b increased the expression of both NFKB1 and IL1B itself, thus suggesting an autocrine loop, and this was revoked by rIL-1Ra ( Figure 6D ). These data, taken together with observations of the increased expression of NFKB1 and IL1B in neutrophils from patients with systemic-onset JIA ( Figure 3E ), indicate that neutrophils are responsive to IL-1b and suggest that the therapeutic efficacy of rIL1Ra in systemic-onset JIA could be at least partially attributed to its effect on neutrophils.
DISCUSSION
This study is the first to describe the phenotype, function, and transcriptome of neutrophils during the systemic inflammatory response of systemic-onset JIA. We showed that the high neutrophil counts at disease onset decreased dramatically after initiation of rIL-1Ra treatment, and found that neutrophils from patients with active systemic-onset JIA up-regulated several immune-related processes and displayed a primed phenotype, which was reversed by IL-1 blockade.
Data on the role of neutrophils in systemic-onset JIA are limited. So far, only 2 studies have described the phenotype of neutrophils in systemic-onset JIA or its adult counterpart, adult-onset Still's disease (30, 31) . Unfortunately, those studies focused on one aspect of neutrophils and/or comprised patients with longstanding disease treated with several immunomodulatory drugs. Since we selected patients at the time of disease onset or a recent flare prior to initiation of therapy, it is more likely that the results of our study are a true reflection of the pathogenesis of the early inflammatory phase of systemic-onset JIA.
Unfortunately, due to the rarity of systemic-onset JIA and the practical limitations that come with neutrophil experiments (e.g., the impossibility of freezing), we were not able to replicate our findings in a separate cohort. Furthermore, small patient numbers and experimental variability made statistical testing sensitive to outliers. Ideally, sequencing experiments are performed in neutrophils of healthy children and patients with systemic-onset JIA during a period of inactive disease. As the phenotype and function of neutrophils from healthy controls and patients with systemic-onset JIA with inactive disease did not show clear differences, we focused our RNA-sequencing analyses on the comparison between active systemic-onset JIA and healthy controls. The large differences in transcriptome between neutrophils from patients with active systemic-onset JIA and neutrophils from healthy controls, in combination with the overlap with the transcriptome of other systemic inflammatory conditions, point toward the notion that there is a similar primed phenotype of neutrophils that cannot be attributed to differences in age or other confounding factors. This is supported by other studies that have shown no differences in neutrophil function between healthy children and adults (32, 33) .
The activated phenotype of neutrophils is in striking contrast to what we and others have observed in natural killer (NK) cells and monocytes from patients with systemic-onset JIA with active disease. Both NK cells and monocytes seem to have switched to a more counteractive or dampened activation state, suggesting that "immune-tolerizing" mechanisms are in place (5, (34) (35) (36) . As neutrophils did not show dampened responses, but rather had increased effector functions, we conclude that neutrophils may be a key player in the early phase of systemic-onset JIA.
The discovery of the TLR-4 ligand LPS as a major regulator of the transcriptome changes in systemic-onset JIA neutrophils, as well as the observed strong overlap in the transcriptome of neutrophils between systemiconset JIA and sepsis or experimental endotoxemia, suggest that in vivo exposure to high levels of TLR-4-stimulatory S100 proteins could explain the inflammatory gene expression in the neutrophils from patients with active systemic-onset JIA. Indeed, several studies have demonstrated the priming of neutrophils after stimulation with S100 proteins (37) (38) (39) (40) (41) (42) . However, other inflammatory proteins, such as IL-1b, might also be responsible for the primed phenotype of neutrophils in systemic-onset JIA.
Neutrophils from patients with active systemiconset JIA showed increased gene expression of IL-1b, inflammasome components, and genes involved in the NF-jB pathway, indicating that there was an increased production of IL-1b. Recent studies highlighted the importance of neutrophils as a source of IL-1b in several models of inflammatory and infectious diseases, and demonstrated the capability of neutrophils to secrete IL-1b in either an inflammasome-dependent or inflammasome-independent manner (43) (44) (45) (46) (47) (48) (49) . Those investigators concluded that, despite the relatively low production of IL-1b by neutrophils compared to monocytes, neutrophils can still be a major source of IL-1b, due to their abundance in the peripheral blood and at the site of inflammation. Furthermore, we found that IL-1b itself can also prime neutrophils, a feature that can be reversed by rIL-1Ra. The dramatic decrease in neutrophil counts in patients with systemic-onset JIA upon initiation of rIL-1Ra therapy suggests that IL-1 and rIL-1Ra can also affect neutrophils in vivo. Taken together, these data extend the IL-1 signature in systemic-onset JIA by describing a novel role for neutrophils. This is supported by a recently published microarray analysis of adult-onset Still's disease, which showed that up-regulation of canakinumab-responsive genes was particularly pronounced in patients with strongly elevated neutrophil numbers (50) . Importantly, we found that patients whose disease duration at first visit to our clinic was relatively short had higher neutrophil counts and more immature neutrophils compared to patients who had already been experiencing symptoms for months. Moreover, albeit in only a limited number of patients, we found that patients with a shorter disease duration and high neutrophil counts had a complete response to rIL-1Ra, whereas patients with a longer time since onset of symptoms and normal neutrophil counts did not achieve inactive disease with rIL-1Ra. Consistent with previous observations (5), these data indicate that neutrophil counts could be a biomarker for the prediction of response to IL-1 blockade and therefore, in 954 TER HAAR ET AL conjunction with other biomarkers, might guide personalized treatment. This requires validation in a different and preferably larger cohort. Furthermore, our observations also fit the hypothesis that the initial phase of systemiconset JIA is characterized by innate immune activation with an important role for neutrophils. This early autoinflammatory phase could represent a "window of opportunity" for the early initiation of IL-1 blocking therapy before the appearance of more autoimmune-related features (2, 3) . In summary, the results of this study indicate that neutrophils play an important role in the early inflammatory phase of systemic-onset JIA. Importantly, the findings confirm that neutrophil numbers and the inflammatory activity of systemic-onset JIA are strongly susceptible to IL-1 blockade.
